A cancer derived mutation in the Retinoblastoma gene with a distinct defect for LXCXE dependent interactions

Shauna A Henley1,3, Sarah M Francis1,3, Jordan Demone1,3, Peter Ainsworth4 and Frederick A Dick*1,2,3

Abstract
Background: The interaction between viral oncoproteins such as Simian virus 40 TAg, adenovirus E1A, and human papilloma virus E7, and the retinoblastoma protein (pRB) occurs through a well characterized peptide sequence, LXCXE, on the viral protein and a well conserved groove in the pocket domain of pRB. Cellular proteins, such as histone deacetylases, also use this mechanism to interact with the retinoblastoma protein to repress transcription at cell cycle regulated genes. For these reasons this region of the pRB pocket domain is thought to play a critical role in growth suppression.

Results: In this study, we identify and characterize a tumor derived allele of the retinoblastoma gene (RB1) that possesses a discrete defect in its ability to interact with LXCXE motif containing proteins that compromises proliferative control. To assess the frequency of similar mutations in the RB1 gene in human cancer, we screened blood and tumor samples for similar alleles. We screened almost 700 samples and did not detect additional mutations, indicating that this class of mutation is rare.

Conclusions: Our work provides proof of principal that alleles encoding distinct, partial loss of function mutations in the retinoblastoma gene that specifically lose LXCXE dependent interactions, are found in human cancer.

Background
The RB1 gene was first identified based on its mutation in retinoblastoma [1,2], however, it has since been found to be absent or misregulated in almost all human cancers [3]. The retinoblastoma protein (pRB) is also thought to be an essential target for inactivation in cancer because it is targeted by viral oncogenes during cellular transformation. The TAg protein product of Simian virus 40, E1A from adenovirus, and E7 from human papilloma virus all contain an LXCXE peptide motif that is essential for transforming activity and it is used to contact the pocket domain of pRB [4-6]. A number of cellular proteins, most notably chromatin regulators such as histone deacetylases and methyltransferases, also use an LXCXE motif to interact with pRB to participate in cell cycle regulation [7]. We have previously mutagenized the pRB pocket domain to map protein interaction sites and these results have been published [8-10]. This work revealed that discrete mutations in RB1, that only affect LXCXE interactions and not E2Fs, are limited to the coding region of exons 21 and 22 (Fig. 1). This is likely because the amino acids encoded by these exons are in close proximity in the three dimensional structure of the pRB pocket domain [11]. Others have also reported that the C-terminal region of pRB, that is phosphorylated by Cyclin/CDKs, can interact with and regulate access to the LXCXE binding cleft [12]. This region is encoded by exon 23. Based on these data we hypothesized that cancer derived mutant alleles of human RB1 in these three exons have the potential to specifically disrupt LXCXE-type interactions in isolation from other interactions with pRB’s pocket domain. Our work demonstrates the existence of this class of mutation in human cancer. We also provide evidence that this type of mutation can compromise pRB’s ability to regulate proliferation even when heterozygous with a wild type copy of the retinoblastoma gene.
**Results and Discussion**

To determine if pRB-LXCXE disrupting mutations arise in human cancer we initially searched the Retinoblastoma Genetics Database [13] and the Catalogue of Somatic Mutations in Cancer (COSMIC) database [14]. A number of missense mutations have been identified that are found in exons 21, 22 or 23 and we have generated expression constructs for them to enable further study (Fig. 1). Additional mutations in these exons exist beyond what we report here. However, they have either been previously characterized, appear to be redundant with mutations that we are studying, or are alleles that are very similar to those tested in our previous alanine scanning experiments. For example, the C706F variant found in small cell lung cancer [15] has been well-characterized in previous studies, and while it is unable to interact with LXCXE proteins, it is also incapable of interacting with E2F transcription factors, among other defects [16-19]. Furthermore, we expect that it is very similar to the retinoblastoma derived C706Y mutant. Based on this reasoning, the mutations listed in Fig. 1 were selected for use in this study because they are unique and uncharacterized. Mutant proteins containing these substitutions were tested for their ability to bind to LXCXE proteins, such as TAg, as a marker for LXCXE-dependent interactions (data not shown). Of the mutants tested, only M704V showed properties similar to the pRB\(^{\Delta L}\) mutant protein that we generated based on crystallographic data to specifically disrupt this interaction (the \(\Delta L\) mutant contains I753A, N757A, and M761A substitutions). The properties of the M704V protein are revealed in experiments using both GST-pulldown and immunoprecipitation approaches (Fig. 2A &2B). Like pRB\(^{\Delta L}\), pRB\(^{M704V}\) retains the ability to interact with E2F3/DP1, but its ability to interact with SV40-TAg is greatly compromised. The similarity in specificity between our synthetic mutant pRB\(^{\Delta L}\) and the cancer derived M704V variant is likely explained by the close proximity of the substituted amino acids in the crystal structure of the pRB pocket [11]. In addition to alterations in structure, mutations can also cause proteins to lose function due to a decrease in protein stability. To examine this possibility, cells expressing wild-type pRB, pRB\(^{\Delta L}\) or pRB\(^{M704V}\) were treated with cycloheximide to block *de novo* protein synthesis. Cells were harvested every 3 hours after treatment for 15 hours and probed for pRB to monitor rates of protein degradation (Fig. 2C). The RB\(^{M704V}\) protein showed similar stability to wild type pRB and pRB\(^{\Delta L}\), with a half-life ranging from 10 to 12 hours across a number of experiments, which is comparable to previous publications [20,21]. Taken together, our data suggests that the pRB\(^{M704V}\) mutant has a specific defect for LXCXE interactions and is stably expressed.

In the initial report of the M704V variant of pRB, it was described as heterozygous [22]. Given that the retinoblastoma gene is thought to be functional until loss of heterozygosity removes the remaining wild type allele, we wondered how much the M704V mutant contributed to the pathogenesis of the tumor where it was found. To address the effects of heterozygosity of the M704V allele, we took advantage of a gene targeted, knock in mouse strain that possesses an analogous allele in its mouse *RB1*
gene (called Rb1ΔL). There are several advantages to using a targeted knock in model over cell culture systems. Initial characterization of the pRBΔL mutant revealed surprisingly few effects in cell culture assays; the mutant protein maintained its ability to induce a cell cycle arrest in RB1 deficient Saos2 cells as well as its ability to repress E2F target genes [8]. This was unexpected because the LXCXE binding cleft region of pRB is highly conserved and confers susceptibility to viral pathogens, suggesting that it must have an important function. To circumvent the limitations of cell culture systems, further studies were performed in fibroblast cells from Rb1ΔL mice. Using these cells, discrete defects in pRBΔL’s ability to control the cell cycle were identified. More specifically, disruption of LXCXE interactions in vivo abrogates G1 arrest in response to exogenous stimuli such as DNA damage or transforming growth factor-β (TGF-β), but does not speed up G1-S phase progression in proliferating cultures of cells [23-25]. For these reasons, we tested the response of Rb1+/+, Rb1ΔL/+ and Rb1ΔL/ΔL primary embryonic fibroblasts to TGF-β treatment. In this way we could carefully examine gene-dosage effects of the Rb1ΔL mutant on growth arrest in an otherwise normal cell. First, we tested the stability of the Rb1ΔL allele in vivo, and found that the steady state levels of pRB in both Rb1ΔL/+ and Rb1ΔL/ΔL cells were similar to wild-type, confirming that this mutation does not affect protein stability (Fig. 3A). Cells were then treated with TGF-β for 24 hours, pulse labelled with bromodeoxyuridine (BrdU), and the percentage of BrdU positive cells was quantified by flow cytometry (Fig. 3B). While the Rb1+/+ fibroblasts exhibited a marked decrease in proliferation in response to TGF-β, Rb1ΔL/ΔL cells showed no significant decrease.
to TGF-β treatment, both the $Rb1ΔL/ΔL$ and the $Rb1ΔL/ΔL$ cells displayed resistance to TGF-β growth arrest. Pair wise comparisons of the percentage of BrdU positive cells following TGF-β treatment between each genotype indicates that they are significantly different ($t$-test, $P < 0.05$). This reveals that loss of LXCXE interactions by even a single $Rb1$ allele significantly reduces TGF-β growth inhibition. The ability of the $Rb1ΔL$ mutation to confer resistance to TGF-β’s cytostatic effect is highly suggestive that the M704V variant of pRB can contribute to cancer susceptibility because even when heterozygous, mutations that disrupt LXCXE interactions compromise pRB’s ability to regulate proliferation.

The mammary specific growth control defects in $Rb1ΔL/ΔL$ mice [24], along with the origin of the M704V variant, suggest that ΔL-like mutations may be found in breast and ovarian cancers. The connection between breast and ovarian cancer is well known and the requirement for LXCXE interactions in TGF-β growth arrest further suggests a link between this type of mutation and these cancers. Indeed, two recent studies suggest that as yet unidentified allelic variants of RB1 may modify the risk of breast and ovarian cancer [26,27]. For these reasons, we sought to identify more alleles of this type from breast and ovarian cancer patients. To search for these alleles, we devised a high resolution melting (HRM) assay. HRM is a highly sensitive method that uses the distinct melting curves of each region of DNA to identify sequences that differ from a known standard. Again, the target of this analysis was $Rb1$ exons 21, 22, and 23 because they can be altered to create alleles like M704V.

To test the sensitivity of HRM at this locus, primers were designed to amplify each exon individually and plasmid constructs were generated that encode either exon 21, 22 or 23 with or without single base pair substitutions from previously characterized $Rb1$ mutations. To detect heterozygous sequence changes in $Rb1$, equal quantities of wild type and mutant version of each construct were mixed, PCR amplified, and subjected to melting analysis alongside human genomic DNA samples (Fig. 4A). When the melt profile is compared to wild type control DNA, a shift in the melting curve is observed. When analyzed by Gene Scanning software, the control heterozygous samples were readily distinguished in a difference plot, validating the sensitivity of this assay for each exon (Fig. 4B). In total 627, genomic DNA samples were analyzed, representing individuals classified as high risk for inherited breast and/or ovarian cancer. To search for mutations in primary tumor specimens, 50 breast and 21 ovarian tumor samples were obtained. These were PCR amplified and directly sequenced using primers specific to each exon because they may be homozygous at the $Rb1$ locus and thus indistinguishable from wild type in our HRM analysis. The results from both methods of screening are summarized in Table 1. No new alleles were detected by this approach.

**Table 1: Summary of mutation detection.**

| Blood samples | Tumor samples |
|---------------|---------------|
|               | Breast        | Ovarian       |
| Exon 21       | Screened 627  | Mutations 0   | Screened 50 | Mutations 0 | Screened 21 | Mutations 0 |
| Exon 22       | Screened 627  | Mutations 0   | Screened 50 | Mutations 0 | Screened 21 | Mutations 0 |
| Exon 23       | Screened 627  | Mutations 0   | Screened 50 | Mutations 0 | Screened 21 | Mutations 0 |

To detect heterozygous sequence changes, peripheral blood samples from breast and/or ovarian cancer patients were subjected to HRM analysis using primers specific to exons 21, 22 and 23. To detect potentially homozygous sequence changes from breast and ovarian tumor samples, PCR amplicons of these exons were directly sequenced.

Conclusions

In this study we sought to identify cancer-associated mutations that specifically target the region of $Rb1$ encoding the LXCXE binding cleft. In this way, our goal was to search for distinct $Rb1$ alleles that are compromised for just one aspect of its function. We characterized an ovarian cancer derived variant of $Rb1$ that possesses biochemical properties that are comparable to our previously published $Rb1ΔL$ mutant allele. We also showed that a single mutant allele of $Rb1$ can significantly decrease the response to TGF-β mediated growth arrest, indicating that the retinoblastoma gene displays haploinsufficiency for growth control. While we were unable to find more examples of this type of allele, our work suggests that cancer types that are characterized by resistance to TGF-β growth arrest and maintain heterozygosity for $Rb1$ may possess this type of mutant allele as a means of overcoming growth inhibitory mechanisms that limit tumor formation.
Methods

Protein interaction analysis
Glutathione S-transferase (GST) pull-down experiments were performed as described in Dick et al. [8]. The GST-RB constructs contain the large pocket of pRB, encompassing amino acids 379 to 928. The GST-RB\textsuperscript{AL} and GST-RB\textsuperscript{M704V} contain I753A, N757A and M761A or M704V substitutions, respectively. In each case, recombinant proteins (or GST as a control) were incubated with whole-cell extracts from C33A cells transfected with either CMV-HA-E2F3 and CMV-HA-DP1, or CMV-TAg. Bound proteins were detected by western blotting using 12CA5 hybridoma supernatant for HA-tagged E2F3/DP1, or mouse monoclonal antibody PAb419 (CalBiochem) for SV40-TAg, followed by a peroxidase conjugated anti-mouse IgG secondary antibody. Input levels of GST-fusions were detected by Coomassie staining.

Immunoprecipitations were performed essentially as described in Siefried et al. [28]. The pRB constructs tested contain either the full-length wild type \textit{RB1} cDNA (CMV-RB) or \textit{RB1} cDNA that has been mutated to create the desired amino acid substitutions (CMV-RB\textsuperscript{AL} and CMV-RB\textsuperscript{M704V}). In brief, C33A cells were transfected with 10 μg of each CMV-RB construct in addition to either 5 μg of CMV-TAg or 5 μg each of CMV-HA-E2F3 and CMV-HA-DP1. To precipitate TAg immune complexes, the PAb419 antibody (CalBiochem) was used, whereas 12CA5 hybridoma supernatant was used to pull down HA-containing immune complexes. In each case, bound pRB was detected by western blotting using the G3-245 α-pRB antibody (BD Pharmingen), as above. HA-E2F3, HA-DP1 and TAg input levels were also detected by western blotting.

Protein stability assay
To assess protein stability, 2.6 × 10\textsuperscript{6} C33A cells were transfected by Ca\textsubscript{3}PO\textsubscript{4} with 45 μg of CMV-RB, CMV-RB\textsuperscript{AL} or CMV-RB\textsuperscript{M704V} in a 15 cm plate. Twenty-four hours post-transfection cells were replated into 6 replicate 6 cm plates. Twenty-four hours after replating, cells were treated with 100 μg/mL cycloheximide and harvested after 0, 3, 6, 9, 12 and 15 hours. To detect pRB, 10 μg of total protein was analyzed by western blotting as described above. Protein levels were quantified by densitometry using a Bio Rad Gel Doc XR gene imager and half-lives were calculated accordingly. To assess the expression of pRB \textit{in vivo}, asynchronously proliferating \textit{Rb1}\textsuperscript{?/?}, \textit{Rb1}\textsuperscript{ΔL/?} and \textit{Rb1}\textsuperscript{ΔL/ΔL} MEFs were harvested and 50 μg of total protein was analyzed by western blotting as described above. Protein levels were quantified by densitometry using a Bio Rad Gel Doc XR gene imager and half-lives were calculated accordingly. To assess the expression of pRB \textit{in vivo}, asynchronously proliferating \textit{Rb1}\textsuperscript{?/?}, \textit{Rb1}\textsuperscript{ΔL/?} and \textit{Rb1}\textsuperscript{ΔL/ΔL} MEFs were harvested and 50 μg of total protein was analyzed by western blotting using the G3-245 α-pRB antibody (BD Pharmingen), as above. HA-E2F3, HA-DP1 and TAg input levels were also detected by western blotting.

TGF-β growth arrest assays
Asynchronously proliferating \textit{Rb1}\textsuperscript{?/?}, \textit{Rb1}\textsuperscript{ΔL/?} and \textit{Rb1}\textsuperscript{ΔL/ΔL} MEFs were treated with 100 pM TGF-β1 (R&D systems) for 24 hours. Cells were then pulse labelled with BrdU

Figure 4 High resolution melting analysis of \textit{RB1} exons 21, 22 and 23. (A) To detect heterozygous sequence changes in \textit{RB1}, constructs were created that encode either exon 21, 22 or 23 with or without single base pair substitutions. Equal quantities of these constructs were mixed, PCR amplified, and subjected to melting analysis alongside human genomic DNA samples. (B) Each DNA sample was analyzed in duplicate and the differences in melting profiles are plotted as a normalized difference plot. Representative difference plots for each exon are shown. In each case the pair of heterozygous plasmid controls (shown in red) is readily distinguishable from the homozygous human samples (shown in blue) by the Gene Scanning software as it assigns the colours.
(RPN201V1, Amersham Biosciences) for 1.5 hours. BrdU incorporation was quantified using flow cytometry on a Beckman-Coulter EPICS XL-MCL instrument, as previously described [29].

**Patient samples**

Peripheral blood DNA samples (627 specimens) from human breast and/or ovarian cancer patients were obtained from the London Health Sciences Centre, Molecular Diagnostics Laboratory (London, ON). All samples were post-testing material from individuals that meet Ontario provincial referral criteria because they are under the age of 35 (173), have three or more cases of breast or ovarian cancer on the same side of the family (155) or otherwise have a pedigree that is strongly suggestive of hereditary breast/ovarian cancer. Frozen breast tumor samples were obtained from the Ontario Tumour Bank. Samples were chosen at random (not based on histological characteristics) from patients between 38 and 87 years of age. All tumor material was derived from the primary site. DNA was isolated from these samples using standard techniques. DNA from ovarian tumor samples was prepared from passage two cells that were isolated from patient ascites. Ovarian samples were from patients between 25 and 85 years of age. DNA was provided courtesy of the Translational Ovarian Cancer Program at the London Health Sciences Centre.

**High resolution melting (HRM) analysis**

HRM analysis was conducted using the Roche Lightcycler 480 HRM kit. In brief, each 20 μL reaction consisted of 10 μL of 2× Master Mix, 0.1875 μM of each primer, 3.0 to 4.0 mM of MgCl2 and 50 ng of genomic DNA. As a positive control, test constructs encoding individual exons with either a single nucleotide change (mutant) or without (wild type) were mixed in equal quantities and 0.1 pg of the resulting mixture was used in place of a genomic DNA sample. The mutant constructs for exon 21 and exon 22 each contain a single G to T substitution (g.160839G>T and g.162027G>T) from previously described [29]. To detect sequence changes in tumor DNA samples, PCR products were generated and directly sequenced (McGill University and Genome Quebec Innovation Centre). Exon 21 products were obtained and sequenced using primers 21F (ttggatataacctcatgtagac) and 21R (cctgttagttatgatgtag). Exons 22 and 23 were amplified in a single reaction using primers 22F (tataatgctgcttaccaagtca) and 23R (aagcaaatggctttcagcgctag) and sequenced using primers 22F and 23R (gegttgcttaatcgc taggingattag).

**Abbreviations**

pRB: retinoblastoma protein; Rb1: human retinoblastoma gene; Rb1: murine retinoblastoma gene; TGF-β: transforming growth factor-beta; BrdU: bromodeoxyuridine; HRM: high resolution melt.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

SAH planned and performed the experiments in Fig. 2 and 4, and Table 1. SMF planned and performed the experiments in Fig. 3. JD planned and supervised the mutation detection experiments in Fig. 4 and Table 1. FAD and SAH wrote the manuscript. All authors have approved the content of this manuscript.

**Acknowledgements**

We would like to thank many past and present laboratory members for contributions during the course of this work. In particular, we are grateful to Alan Stuart, Lindsay Jordan, Steven Russell, and Janet Lew for assistance with plasmid constructions and mutation screening. We are thankful for the generosity of Drs. Trevor Shepherd and Gabe DiMattia, and the Translational Ovarian Cancer Program for providing ovarian cancer derived patient DNA. SMF is supported by a Translational Breast Cancer Studentship from the LRCP. SAH is supported by a post-doctoral fellowship from the Canadian Breast Cancer Foundation, Ontario Chapter. SMF and SAH are thankful for previous stipend support from the Canadian Cancer Society. Grant funding from the Cancer Research Society supported this project.

**Author Details**

1. London Regional Cancer Program, 790 Commissioners Road East, London, Ontario, N6A 4L6, Canada. 2. Children’s Health Research Institute, 800 Commissioners Road East, London, Ontario, N6A 4L6, Canada. 3. Department of Biochemistry, University of Western Ontario, 1151 Richmond Street, London, Ontario, N6A 5B8, Canada. 4. Molecular Diagnostics Laboratory, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario, N6A 4L6, Canada.

Received: 18 January 2010 Accepted: 18 March 2010 Published: 18 March 2010

**References**

1. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 1986, 323:643-646.
2. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY: Human retinoblastoma susceptibility gene: cloning, identification, and sequence., Science 1987, 235:1394-1399.

3. Sherr CJ, McCormick F: The Rb and p53 pathways in cancer., Cancer Cell 2002, 2:103-112.

4. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM: SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene., Cell 1988, 54:275-283.

5. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E: Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product., Nature 1988, 334:124-129.

6. Dyson N, Howley PM, Munger K, Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product., Science 1989, 243:894-917.

7. Dick F: Structure-Function Analysis of the Retinoblastoma Protein-Is the Whole a Sum of its Parts? Cell Div 2007, 2:26.

8. Dick FA, Salhaimer E, Dyson NJ: Mutagenesis of the pRB pocket domain reveals that cell cycle arrest functions are separable from binding to viral oncoproteins., Mol Cell Biol 2000, 20:3715-3727.

9. Dick FA, Dyson N: Three Regions of the pRB Pocket Domain Affect Its Inactivation by Human Papillomavirus E7 Proteins., J Virol 2002, 76:6224-6234.

10. Dick FA, Dyson N: pRB Contains an E2F1 Specific Binding Domain that Allows E2F1 Induced Apoptosis to Be Regulated Separately from other E2F Activities., Mol Cell 2003, 12:639-649.

11. Lee J-O, Russo AA, Pavletich NP: Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7., Nature 1998, 391:859-865.

12. Harbour J, Luo R, Dei Sant i A, Postigo A, Dean D: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1., Cell 1999, 98:859-869.

13. Lohmann DR: Rb1 Gene Mutations in Retinoblastoma., Human Mut 1999, 14:283-288.

14. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futeal PA, Stratton MR, Wooster R: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website., Br J Cancer 2004, 91:355-358.

15. Kratke RA, Stottsen GA, Lin AY, Shadforth D, Quayle L, Kjaer SK, Dicioccio RA, Dunning AM, Hoggard E, Whitmore AS, McGuire V, Lesueur F, Easton DF, Jacobs IJ, Ponder BA, Gayther SA, Pharoah PD: Common Variants in RB1 Gene and Risk of Invasive Ovarian Cancer., Cancer Res 2006, 66:10220-10226.

16. Lesueur F, Song H, Ahmed S, Scurcinari C, Jordan C, Luben R, Easton DF, Dussling AM, Pharoah PD, Ponder BA: Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population., Br J Cancer 2006, 94:1921-1926.

17. Seifried LA, Talluri S, Cecchini M, Julian LM, Mymyky JS, Dick FA: pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption., J Virol 2008, 82:4511-4520.

18. Classon M, Salama SR, Gorka C, Mulloy P, Braun P, Harlow EE: Combinatorial roles for pRB, p107 and p130 in E2F-mediated cell cycle control., Proc Natl Acad Sci USA 2000, 97:10820-10825.

19. Horowitz JM, Park SH, Bogemmenn E, Cheng JC, Yandell DW, Kaye FI, Minna JD, Dryja TP, Weinberg RA: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells., Proc Natl Acad Sci USA 1990, 87:2775-2779.

20. Liu Z, Song Y, Bai B, Cowell JK: Germline mutations in the RB1 gene in patients with hereditary retinoblastoma., Genes Chromosomes Cancer 1995, 14:277-284.

21. Driscoll B, Wu L, Buckley S, Hall FL, Anderson KD, Warburton D: Cyclin D1 antisense RNA destabilizes pRB and retards lung cancer cell growth., Am J Physiol 1997, 273:L941-949.

22. Yaginuma Y, Hayashi H, Kawai K, Kurakane T, Saitoh Y, Kitamura S, Sengoku K, Ishikawa H: Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines., Exp Cell Res 1997, 233:233-239.

23. Talluri S, Isaac CE, Ahmad M, Henley SA, Francis SM, Martens AL, Bremner R, Dick FA: A G1 checkpoint mediated by the retinoblastoma protein that is dispensable in terminal differentiation but essential for senescence., Mol Cell Biol 2010, 30:948-960.

24. Francis SM, Bergsied J, Isaac CE, Coschi CH, Martens AL, Hojjila CV, Chakraborti S, Damatte CE, Khoka R, Wang YJ, Dick FA: A functional connection between pRB and transforming growth factor beta in growth inhibition and mammary gland development., Mol Cell Biol 2009, 29:4455-4466.

25. Isaac CE, Francis SM, Martens AL, Julian LM, Seifried LA, Erdmann N, Binne UK, Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product., J Virol 2002, 20:3715-3727.

26. Qin XQ, Chittenden T, Livingston DM, Kaelin WG Jr: The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F Activities., Mol Cell 2003, 12:639-649.

27. Dick FA, Dyson N: pRB Contains an E2F1 Specific Binding Domain that Allows E2F1 Induced Apoptosis to Be Regulated Separately from other E2F Activities., Mol Cell 2003, 12:639-649.

28. Seifried LA, Talluri S, Cecchini M, Julian LM, Mymyky JS, Dick FA: pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption., J Virol 2008, 82:4511-4520.

29. Classon M, Salama SR, Gorka C, Mulloy P, Braun P, Harlow EE: Combinatorial roles for pRB, p107 and p130 in E2F-mediated cell cycle control., Proc Natl Acad Sci USA 2000, 97:10820-10825.

30. Horowitz JM, Park SH, Bogemmenn E, Cheng JC, Yandell DW, Kaye FI, Minna JD, Dryja TP, Weinberg RA: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells., Proc Natl Acad Sci USA 1990, 87:2775-2779.

31. Liu Z, Song Y, Bai B, Cowell JK: Germline mutations in the RB1 gene in patients with hereditary retinoblastoma., Genes Chromosomes Cancer 1995, 14:277-284.